 CAMBRIDGE, Mass.--BUSINESS WIRE--Gemini Therapeutics, Inc. Nasdaq: GMTX, a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration AMD, today reported its financial results for the first quarter ended March 31, 2021 and provided a business update. During the first quarter, we continued to make significant progress in the clinical development of GEM103 and look forward to releasing initial data from the ongoing Ph 